People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as mental health medicine. A recent approval made by the FDA could be a great step ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder, ...

Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced ...